Brief: Neubase Therapeutics Says At Sept. 30, 2019, Co Had Cash And Cash Equivalents Of About $10.3 Mln
09/01/2020 22:21
Jan 9 (Reuters) - NeuBase Therapeutics Inc NBSE.O :
* NEUBASE THERAPEUTICS REPORTS FINANCIAL RESULTS FOR FISCAL
YEAR
2019
* NEUBASE THERAPEUTICS INC - AT SEPTEMBER 30, 2019, COMPANY
HAD
CASH AND CASH EQUIVALENTS OF ABOUT $10.3 MILLION
* NEUBASE THERAPEUTICS - BELIEVES THAT CURRENT CASH BALANCE
WILL
PROVIDE SUFFICIENT CAPITAL TO FUND OPERATIONS THROUGH END OF
FISCAL YEAR 2020
Source text for Eikon: ID:nGNX9FD0dh
Further company coverage: NBSE.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on NeuBase Therapeutics
See all newsBrief: Neubase Therapeutics, On May 2, Was Notified By Nasdaq On Not Regained Compliance With Minimum Bid Price Requirement
Brief: Neubase Therapeutics Announces Receipt Of Notice From Nasdaq
U.S. STOCKS ON THE MOVE-TPG, R1 RCM, Zoom
U.S. STOCKS ON THE MOVE-Micron, Krystal Biotech, Pilgrim's Pride
U.S. STOCKS ON THE MOVE-Domino's Pizza, Voyager, Freshpet